Leerink Partners Initiates Coverage On Sagimet Biosciences with Outperform Rating, Announces Price Target of $26

Benzinga · 03/25 10:46
Leerink Partners analyst Thomas Smith initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Outperform rating and announces Price Target of $26.